Nature Communications (Jan 2024)

Levels of complement factor H-related 4 protein do not influence susceptibility to age-related macular degeneration or its course of progression

  • M. A. Zouache,
  • B. T. Richards,
  • C. M. Pappas,
  • R. A. Anstadt,
  • J. Liu,
  • T. Corsetti,
  • S. Matthews,
  • N. A. Seager,
  • S. Schmitz-Valckenberg,
  • M. Fleckenstein,
  • W. C. Hubbard,
  • J. Thomas,
  • J. L. Hageman,
  • B. L. Williams,
  • G. S. Hageman

DOI
https://doi.org/10.1038/s41467-023-44605-0
Journal volume & issue
Vol. 15, no. 1
pp. 1 – 17

Abstract

Read online

Abstract Dysregulation of the alternative pathway (AP) of the complement system is a significant contributor to age-related macular degeneration (AMD), a primary cause of irreversible vision loss worldwide. Here, we assess the contribution of the liver-produced complement factor H-related 4 protein (FHR-4) to AMD initiation and course of progression. We show that FHR-4 variation in plasma and at the primary location of AMD-associated pathology, the retinal pigment epithelium/Bruch’s membrane/choroid interface, is entirely explained by three independent quantitative trait loci (QTL). Using two distinct cohorts composed of a combined 14,965 controls and 20,741 cases, we ascertain that independent QTLs for FHR-4 are distinct from variants causally associated with AMD, and that FHR-4 variation is not independently associated with disease. Additionally, FHR-4 does not appear to influence AMD progression course among patients with disease driven predominantly by AP dysregulation. Modulation of FHR-4 is therefore unlikely to be an effective therapeutic strategy for AMD.